[Real-life experiences with Brolucizumab in recalcitrant neovascular age-related macular degeneration].

Marius BookM ZieglerK RothausH FaatzM GutfleischG SpitalA LommatzschD Pauleikhoff

Published in: Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft (2021)

Intravitreal brolucizumab treatment can achieve significant reductions particularly of SRF and sub-RPE in patients refractory to previous anti-VEGF treatment. Future studies should further investigate the effects of brolucizumab in patients with recalcitrant nAMD.

Keyphrases

age related macular degeneration
vascular endothelial growth factor
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
mental health
endothelial cells
combination therapy
prognostic factors
patient reported outcomes
current status